These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24473897)

  • 61. A quantum-dot based protein module for in vivo monitoring of protease activity through fluorescence resonance energy transfer.
    Biswas P; Cella LN; Kang SH; Mulchandani A; Yates MV; Chen W
    Chem Commun (Camb); 2011 May; 47(18):5259-61. PubMed ID: 21445447
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
    Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
    Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
    Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
    J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [HIV-1 protease inhibitors in review].
    Hilgeroth A
    Pharm Unserer Zeit; 1998 Jan; 27(1):22-5. PubMed ID: 9562781
    [No Abstract]   [Full Text] [Related]  

  • 67. Quantitative assessment of in vivo HIV protease activity using genetically engineered QD-based FRET probes.
    Cella LN; Biswas P; Yates MV; Mulchandani A; Chen W
    Biotechnol Bioeng; 2014 Jun; 111(6):1082-7. PubMed ID: 24473897
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.
    Wensing AM; van Maarseveen NM; Nijhuis M
    Antiviral Res; 2010 Jan; 85(1):59-74. PubMed ID: 19853627
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Resistance to protease inhibitors.
    Kuritzkes DR
    J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of plant extracts on HIV-1 protease.
    Filho JR; de Sousa Falcão H; Batista LM; Filho JM; Piuvezam MR
    Curr HIV Res; 2010 Oct; 8(7):531-44. PubMed ID: 20946094
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.